11.2 Capital is on record against 42 companies.
We invest at the early stage, focusing on deep-tech verticals including AI, cybersecurity, quantum, robotics, space tech, and synthetic biology, with a rare emphasis on bioengineering. Our geographic focus is global, leveraging technically deep partners to support complex R&D and product development.